{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:26:37Z","timestamp":1780046797798,"version":"3.53.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10620-025-09128-2","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:38:49Z","timestamp":1750138729000},"page":"2990-3004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation Therapy for Abdominal or Pelvic Cancer Treatment in Patients with Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.1007","volume":"70","author":[{"given":"Mario El","family":"Hayek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil El Hage","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi H.","family":"Mourad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"9128_CR1","doi-asserted-by":"publisher","unstructured":"Kilic Y, Kamal S, Jaffar F, Sriranganathan D, Quraishi MN, Segal JP. Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. Published online April 12, 2023:izad061. https:\/\/doi.org\/10.1093\/ibd\/izad061.","DOI":"10.1093\/ibd\/izad061."},{"key":"9128_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2019.02.004.","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G et al. A comprehensive review and update on ulcerative colitis. Dis-Mon DM. 2019;65:100851. https:\/\/doi.org\/10.1016\/j.disamonth.2019.02.004.","journal-title":"Dis-Mon DM."},{"key":"9128_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001.","volume":"64","author":"M Gajendran","year":"2018","unstructured":"Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn\u2019s disease. Dis-Mon DM. 2018;64:20\u201357. https:\/\/doi.org\/10.1016\/j.disamonth.2017.07.001.","journal-title":"Dis-Mon DM."},{"key":"9128_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872.","volume":"35","author":"WY Mak","year":"2020","unstructured":"Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380\u2013389. https:\/\/doi.org\/10.1111\/jgh.14872.","journal-title":"J Gastroenterol Hepatol."},{"key":"9128_CR5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.20524\/aog.2024.0909.","volume":"37","author":"S Alsakarneh","year":"2024","unstructured":"Alsakarneh S, Ahmed M, Jaber F et al. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990\u20132019. Ann Gastroenterol. 2024;37:527\u2013535. https:\/\/doi.org\/10.20524\/aog.2024.0909.","journal-title":"Ann Gastroenterol."},{"key":"9128_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.20524\/aog.2024.0894.","volume":"37","author":"S Alsakarneh","year":"2024","unstructured":"Alsakarneh S, Hassan K, Jaber F et al. The national burden of inflammatory bowel disease in the United States from 1990\u20132019: results from the Global Burden of Disease study database. Ann Gastroenterol. 2024;37:427\u2013435. https:\/\/doi.org\/10.20524\/aog.2024.0894.","journal-title":"Ann Gastroenterol."},{"key":"9128_CR7","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0.","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet Lond Engl. 2017;390:2769\u20132778. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","journal-title":"Lancet Lond Engl."},{"key":"9128_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34.","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205\u2013217. https:\/\/doi.org\/10.1038\/nrgastro.2015.34.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9128_CR9","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794.","volume":"22","author":"JE Axelrad","year":"2016","unstructured":"Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22:4794\u20134801. https:\/\/doi.org\/10.3748\/wjg.v22.i20.4794.","journal-title":"World J Gastroenterol."},{"key":"9128_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.gtc.2022.05.003.","volume":"51","author":"AS Faye","year":"2022","unstructured":"Faye AS, Holmer AK, Axelrad JE. Cancer in Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2022;51:649\u2013666. https:\/\/doi.org\/10.1016\/j.gtc.2022.05.003.","journal-title":"Gastroenterol Clin North Am."},{"key":"9128_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJMra1403718.","volume":"372","author":"L Beaugerie","year":"2015","unstructured":"Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441\u20131452. https:\/\/doi.org\/10.1056\/NEJMra1403718.","journal-title":"N Engl J Med."},{"key":"9128_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cgh.2024.03.032.","volume":"22","author":"JE Axelrad","year":"2024","unstructured":"Axelrad JE, Hashash JG, Itzkowitz SH. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2024;22:1365\u20131372. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.032.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9128_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035.","volume":"162","author":"SC Shah","year":"2022","unstructured":"Shah SC, Itzkowitz SH. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology. 2022;162:715-730.e3. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.035.","journal-title":"Gastroenterology."},{"key":"9128_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/gut.48.4.526.","volume":"48","author":"JA Eaden","year":"2001","unstructured":"Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526\u2013535. https:\/\/doi.org\/10.1136\/gut.48.4.526.","journal-title":"Gut."},{"key":"9128_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.suronc.2013.08.002","volume":"22","author":"AAP Slesser","year":"2013","unstructured":"Slesser AAP, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol. 2013;22:230\u2013237. https:\/\/doi.org\/10.1016\/j.suronc.2013.08.002.","journal-title":"Surg Oncol."},{"key":"9128_CR16","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x.","volume":"100","author":"T Jess","year":"2005","unstructured":"Jess T, Gamborg M, Matzen P, Munkholm P, S\u00f8rensen TIA. Increased risk of intestinal cancer in Crohn\u2019s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724\u20132729. https:\/\/doi.org\/10.1111\/j.1572-0241.2005.00287.x.","journal-title":"Am J Gastroenterol."},{"key":"9128_CR17","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ibd.22889.","volume":"18","author":"H Sokol","year":"2012","unstructured":"Sokol H, Beaugerie L, Maynadi\u00e9 M et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063\u20132071. https:\/\/doi.org\/10.1002\/ibd.22889.","journal-title":"Inflamm Bowel Dis."},{"key":"9128_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrgastro.2016.208.","volume":"14","author":"MF Neurath","year":"2017","unstructured":"Neurath MF. Current ad emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269\u2013278. https:\/\/doi.org\/10.1038\/nrgastro.2016.208.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"9128_CR19","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7.","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet Lond Engl. 2009;374:1617\u20131625. https:\/\/doi.org\/10.1016\/S0140-6736(09)61302-7.","journal-title":"Lancet Lond Engl."},{"key":"9128_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026.","volume":"12","author":"A Lopez","year":"2014","unstructured":"Lopez A, Mounier M, Bouvier AM et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:1324\u20131329. https:\/\/doi.org\/10.1016\/j.cgh.2014.02.026.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9128_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033.","volume":"12","author":"S Singh","year":"2014","unstructured":"Singh S, Nagpal SJS, Murad MH et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:210\u2013218. https:\/\/doi.org\/10.1016\/j.cgh.2013.04.033.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9128_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024.","volume":"8","author":"MD Long","year":"2010","unstructured":"Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2010;8:268\u2013274. https:\/\/doi.org\/10.1016\/j.cgh.2009.11.024.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"9128_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/apt.13466.","volume":"43","author":"A Bourrier","year":"2016","unstructured":"Bourrier A, Carrat F, Colombel JF et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43:252\u2013261. https:\/\/doi.org\/10.1111\/apt.13466.","journal-title":"Aliment Pharmacol Ther."},{"key":"9128_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635.","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9:193\u2013199. https:\/\/doi.org\/10.7150\/ijms.3635.","journal-title":"Int J Med Sci."},{"key":"9128_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.hoc.2019.08.017.","volume":"34","author":"SC Kamran","year":"2020","unstructured":"Kamran SC, D\u2019Amico AV. Radiation Therapy for Prostate Cancer. Hematol Oncol Clin North Am. 2020;34:45\u201369. https:\/\/doi.org\/10.1016\/j.hoc.2019.08.017.","journal-title":"Hematol Oncol Clin North Am."},{"key":"9128_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.soc.2013.02.010.","volume":"22","author":"BG Czito","year":"2013","unstructured":"Czito BG, Meyer J. Radiation therapy in anal and rectal cancer. Surg Oncol Clin N Am. 2013;22:525\u2013543. https:\/\/doi.org\/10.1016\/j.soc.2013.02.010.","journal-title":"Surg Oncol Clin N Am."},{"key":"9128_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/cco-20-89.","volume":"10","author":"W Chen","year":"2021","unstructured":"Chen W, Chiang CL, Dawson LA. Efficacy and safety of radiotherapy for primary liver cancer. Chin Clin Oncol. 2021;10:9. https:\/\/doi.org\/10.21037\/cco-20-89.","journal-title":"Chin Clin Oncol."},{"key":"9128_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.soc.2017.01.012.","volume":"26","author":"SN Badiyan","year":"2017","unstructured":"Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surg Oncol Clin N Am. 2017;26:431\u2013453. https:\/\/doi.org\/10.1016\/j.soc.2017.01.012.","journal-title":"Surg Oncol Clin N Am."},{"key":"9128_CR29","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.21037\/jgo-22-138.","volume":"13","author":"S Bodofsky","year":"2022","unstructured":"Bodofsky S, Freeman RH, Hong SS et al. Inflammatory bowel disease-associated malignancies and considerations for radiation impacting bowel: a scoping review. J Gastrointest Oncol. 2022;13:2565\u20132582. https:\/\/doi.org\/10.21037\/jgo-22-138.","journal-title":"J Gastrointest Oncol."},{"key":"9128_CR30","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/j.prro.2015.03.002.","volume":"5","author":"S Cherian","year":"2015","unstructured":"Cherian S, Kittel JA, Reddy CA et al. Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. Pract Radiat Oncol. 2015;5:e437\u2013e442. https:\/\/doi.org\/10.1016\/j.prro.2015.03.002.","journal-title":"Pract Radiat Oncol."},{"key":"9128_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00384-014-2103-8.","volume":"30","author":"BW Chang","year":"2015","unstructured":"Chang BW, Kumar AMS, Koyfman SA, Kalady M, Lavery I, Abdel-Wahab M. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits. Int J Colorectal Dis. 2015;30:403\u2013408. https:\/\/doi.org\/10.1007\/s00384-014-2103-8.","journal-title":"Int J Colorectal Dis."},{"key":"9128_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/COC.0000000000000010.","volume":"38","author":"EC White","year":"2015","unstructured":"White EC, Murphy JD, Chang DT, Koong AC. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy. Am J Clin Oncol. 2015;38:564\u2013569. https:\/\/doi.org\/10.1097\/COC.0000000000000010.","journal-title":"Am J Clin Oncol."},{"key":"9128_CR33","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/j.prro.2014.09.004.","volume":"5","author":"CT Murphy","year":"2015","unstructured":"Murphy CT, Heller S, Ruth K et al. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. Pract Radiat Oncol. 2015;5:e215\u2013e222. https:\/\/doi.org\/10.1016\/j.prro.2014.09.004.","journal-title":"Pract Radiat Oncol."},{"key":"9128_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rpor.2016.10.005.","volume":"22","author":"MM Gestaut","year":"2017","unstructured":"Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with Inflammatory Bowel Disease. Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol. 2017;22:77\u201382. https:\/\/doi.org\/10.1016\/j.rpor.2016.10.005.","journal-title":"Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol."},{"key":"9128_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.21037\/jgo.2017.01.13.","volume":"8","author":"P Annede","year":"2017","unstructured":"Annede P, Seisen T, Klotz C et al. Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. J Gastrointest Oncol. 2017;8:173\u2013179. https:\/\/doi.org\/10.21037\/jgo.2017.01.13.","journal-title":"J Gastrointest Oncol."},{"key":"9128_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.radonc.2017.02.009.","volume":"123","author":"SL Bosch","year":"2017","unstructured":"Bosch SL, van Rooijen SJ, B\u00f6kkerink GMJ et al. Acute toxicity and surgical complications after preoperative (chemo)radiation therapy for rectal cancer in patients with inflammatory bowel disease. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;123:147\u2013153. https:\/\/doi.org\/10.1016\/j.radonc.2017.02.009.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol."},{"key":"9128_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.clon.2018.06.007.","volume":"30","author":"W Mohammed","year":"2018","unstructured":"Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease. Clin Oncol R Coll Radiol G B. 2018;30:534\u2013538. https:\/\/doi.org\/10.1016\/j.clon.2018.06.007.","journal-title":"Clin Oncol R Coll Radiol G B."},{"key":"9128_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ijrobp.2019.08.023.","volume":"105","author":"R Mudgway","year":"2019","unstructured":"Mudgway R, Bryant AK, Heide ES et al. A Matched Case-Control Analysis of Clinical Outcomes for Patients With Inflammatory Bowel Disease and Rectal Cancer Treated With Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;105:994\u20131004. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.023.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ibd\/izz175.","volume":"26","author":"LA Feagins","year":"2020","unstructured":"Feagins LA, Kim J, Chandrakumaran A et al. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy. Inflamm Bowel Dis. 2020;26:728\u2013733. https:\/\/doi.org\/10.1093\/ibd\/izz175.","journal-title":"Inflamm Bowel Dis."},{"key":"9128_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13014-021-01850-1.","volume":"16","author":"JW Lischalk","year":"2021","unstructured":"Lischalk JW, Blacksburg S, Mendez C et al. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease. Radiat Oncol Lond Engl. 2021;16:126. https:\/\/doi.org\/10.1186\/s13014-021-01850-1.","journal-title":"Radiat Oncol Lond Engl."},{"key":"9128_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100759.","volume":"6","author":"JE Juarez","year":"2021","unstructured":"Juarez JE, Romero T, Mantz CA et al. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Adv Radiat Oncol. 2021;6:100759. https:\/\/doi.org\/10.1016\/j.adro.2021.100759.","journal-title":"Adv Radiat Oncol."},{"key":"9128_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ctro.2021.01.007.","volume":"27","author":"BGL Vanneste","year":"2021","unstructured":"Vanneste BGL, Van Limbergen EJ, Marcelissen T et al. Is prostate cancer radiotherapy using implantable rectum spacers safe and effective in inflammatory bowel disease patients? Clin Transl Radiat Oncol. 2021;27:121\u2013125. https:\/\/doi.org\/10.1016\/j.ctro.2021.01.007.","journal-title":"Clin Transl Radiat Oncol."},{"key":"9128_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/apt.16176.","volume":"53","author":"D Broussard","year":"2021","unstructured":"Broussard D, Rivi\u00e8re P, Bonnet J et al. Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Aliment Pharmacol Ther. 2021;53:400\u2013409. https:\/\/doi.org\/10.1111\/apt.16176.","journal-title":"Aliment Pharmacol Ther."},{"key":"9128_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/s0360-3016(01)01629-7.","volume":"51","author":"DY Song","year":"2001","unstructured":"Song DY, Lawrie WT, Abrams RA et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001;51:455\u2013459. https:\/\/doi.org\/10.1016\/s0360-3016(01)01629-7.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.brachy.2012.04.008.","volume":"12","author":"HH Pai","year":"2013","unstructured":"Pai HH, Keyes M, Morris WJ, Christie J. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy. 2013;12:126\u2013133. https:\/\/doi.org\/10.1016\/j.brachy.2012.04.008.","journal-title":"Brachytherapy."},{"key":"9128_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0360-3016(97)00583-x.","volume":"40","author":"A Grann","year":"1998","unstructured":"Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 1998;40:135\u2013138. https:\/\/doi.org\/10.1016\/s0360-3016(97)00583-x.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR47","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ijrobp.2006.05.027.","volume":"66","author":"CA Peters","year":"2006","unstructured":"Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2006;66:424\u2013429. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.05.027.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/s0360-3016(99)00374-0.","volume":"46","author":"CG Willett","year":"2000","unstructured":"Willett CG, Ooi CJ, Zietman AL et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys. 2000;46:995\u2013998. https:\/\/doi.org\/10.1016\/s0360-3016(99)00374-0.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/s0360-3016(99)00091-7.","volume":"44","author":"S Green","year":"1999","unstructured":"Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:835\u2013840. https:\/\/doi.org\/10.1016\/s0360-3016(99)00091-7.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR50","doi-asserted-by":"publisher","unstructured":"Gnanapandithan K, Stuessel LG, Shen B, et al. Pelvic Radiation Therapy Increases Risk of Pouch Failure in Patients with Inflammatory Bowel Disease and Ileal Pouch. Dig Dis Sci. Published online August 1, 2024. https:\/\/doi.org\/10.1007\/s10620-024-08576-6.","DOI":"10.1007\/s10620-024-08576-6."},{"key":"9128_CR51","doi-asserted-by":"publisher","unstructured":"Shirato H, Le QT, Kobashi K, et al. Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res (Tokyo). 2018;59(suppl_1):i2-i10. https:\/\/doi.org\/10.1093\/jrr\/rrx092.","DOI":"10.1093\/jrr\/rrx092."},{"key":"9128_CR52","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2147\/CMAR.S351744.","volume":"14","author":"K Koka","year":"2022","unstructured":"Koka K, Verma A, Dwarakanath BS, Papineni RVL. Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment. Cancer Manag Res. 2022;14:1421\u20131429. https:\/\/doi.org\/10.2147\/CMAR.S351744.","journal-title":"Cancer Manag Res."},{"key":"9128_CR53","unstructured":"Mayer C, Gasalberti DP, Kumar A. Brachytherapy. In: StatPearls. StatPearls Publishing; 2024. Accessed February 29, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562190\/"},{"key":"9128_CR54","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr. 2021;112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","DOI":"10.1016\/j.ad.2019.05.009."},{"key":"9128_CR55","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C.","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341\u20131346. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"9128_CR56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/gutjnl-2017-313789.","volume":"67","author":"S Gerassy-Vainberg","year":"2018","unstructured":"Gerassy-Vainberg S, Blatt A, Danin-Poleg Y et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut. 2018;67:97\u2013107. https:\/\/doi.org\/10.1136\/gutjnl-2017-313789.","journal-title":"Gut."},{"key":"9128_CR57","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(13)70504-7.","volume":"15","author":"MR Ferreira","year":"2014","unstructured":"Ferreira MR, Muls A, Dearnaley DP, Andreyev HJN. Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. Lancet Oncol. 2014;15:e139\u2013e147. https:\/\/doi.org\/10.1016\/S1470-2045(13)70504-7.","journal-title":"Lancet Oncol."},{"key":"9128_CR58","doi-asserted-by":"publisher","first-page":"110674","DOI":"10.1016\/j.biopha.2020.110674.","volume":"131","author":"L Shao","year":"2020","unstructured":"Shao L, Li M, Zhang B, Chang P. Bacterial dysbiosis incites Th17 cell revolt in irradiated gut. Biomed Pharmacother. 2020;131:110674. https:\/\/doi.org\/10.1016\/j.biopha.2020.110674.","journal-title":"Biomed Pharmacother."},{"key":"9128_CR59","doi-asserted-by":"publisher","first-page":"586392","DOI":"10.3389\/fcimb.2021.586392.","volume":"11","author":"Y Jian","year":"2021","unstructured":"Jian Y, Zhang D, Liu M, Wang Y, Xu ZX. The Impact of Gut Microbiota on Radiation-Induced Enteritis. Front Cell Infect Microbiol. 2021;11:586392. https:\/\/doi.org\/10.3389\/fcimb.2021.586392.","journal-title":"Front Cell Infect Microbiol."},{"key":"9128_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2020.10.033.","volume":"156","author":"M Tonneau","year":"2021","unstructured":"Tonneau M, Elkrief A, Pasquier D et al. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. Radiother Oncol. 2021;156:1\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2020.10.033.","journal-title":"Radiother Oncol."},{"key":"9128_CR61","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clon.2015.05.001.","volume":"27","author":"D Tromp","year":"2015","unstructured":"Tromp D, Christie DRH. Acute and Late Bowel Toxicity in Radiotherapy Patients with Inflammatory Bowel Disease: A Systematic Review. Clin Oncol R Coll Radiol G B. 2015;27:536\u2013541. https:\/\/doi.org\/10.1016\/j.clon.2015.05.001.","journal-title":"Clin Oncol R Coll Radiol G B."},{"key":"9128_CR62","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.prro.2023.04.006.","volume":"13","author":"M Trotta","year":"2023","unstructured":"Trotta M, Patel KR, Singh S, Verma V, Ryckman J. Safety of Radiation Therapy in Patients With Prostate Cancer and Inflammatory Bowel Disease: A Systematic Review. Pract Radiat Oncol. 2023;13:454\u2013465. https:\/\/doi.org\/10.1016\/j.prro.2023.04.006.","journal-title":"Pract Radiat Oncol."},{"key":"9128_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tipsro.2018.01.004.","volume":"6","author":"BGL Vanneste","year":"2018","unstructured":"Vanneste BGL, Van Limbergen EJ, van de Beek K, van Lin E, Lutgens L, Lambin P. A biodegradable rectal balloon implant to protect the rectum during prostate cancer radiotherapy for a patient with active Crohn\u2019s disease. Tech Innov Patient Support Radiat Oncol. 2018;6:1\u20134. https:\/\/doi.org\/10.1016\/j.tipsro.2018.01.004.","journal-title":"Tech Innov Patient Support Radiat Oncol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09128-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09128-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09128-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T05:17:28Z","timestamp":1756963048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09128-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9128"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09128-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Francis Farraye has served on advisory boards for AbbVie, Avalo Therapeutics, Bausch, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, Viatris and sits on DSMB for Eli Lilly Dr. Jana G. Hashash has served on an Advisory Board for Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}